CLL Videos

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.

At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.

At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...

At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.

At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.

At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...

Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.

At the 2023 EHA meeting in Frankfurt, Germany, Susan M. O'Brien, MD, provided insights into the latest frontline therapeutic options for patients with chronic lymphocytic leukemia.

At the 2023 EHA Congress, Jennifer Brown, MD, presented study findings on mechanisms of resistance to pirtobrutinib among patients with chronic lymphocytic leukemia pre-treated with a covalent BTK inhibitor.

At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.